Activation of AKT/GSK3β pathway by TDZD-8 attenuates kainic acid induced neurodegeneration but not seizures in mice

NeuroToxicology

Volumn 46, Issue , 2015, Pages 44-52

  Bhowmik, Malay ^a   Khanam, Razia ^a   Saini, Neeru ^b   Vohora, Divya ^a  

^a HAMDARD UNIVERSITY   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

4 Benzyl 2 methyl 1,2,4 thiadiazolidine 3,5 dione (TDZD 8); Apoptosis; Glycogen synthase kinase 3 (GSK3 ); Kainic acid (KA); Neurodegeneration

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; KAINIC ACID; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SERINE; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; AMINO ACID RECEPTOR STIMULATING AGENT; BCL2 PROTEIN, MOUSE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL LOSS; CONTROLLED STUDY; DENTATE GYRUS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; EXCITOTOXICITY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; LOW DRUG DOSE; MALE; MICROSCOPY; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; SEIZURES; SIGNAL TRANSDUCTION;

MUS;

ANALYSIS OF VARIANCE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BRAIN; CASPASE 3; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGONISTS; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; KAINIC ACID; MALE; MICE; NEURODEGENERATIVE DISEASES; ONCOGENE PROTEIN V-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SEIZURES; SIGNAL TRANSDUCTION; THIADIAZOLES;

EID: 84919898253     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2014.11.008     Document Type: Article

References (62)

1. Acharya M.M., Hattiangady B., Shetty A.K. Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 2008, 84:363-404.
2. Arabadzisz D., Antal K., Parpan F., Emri Z., Fritschy J.M. Epileptogenesis and chronic seizures in a mouse model of temporal lobe epilepsy are associated with distinct EEG patterns and selective neurochemical alterations in the contralateral hippocampus. Exp Neurol 2005, 194:76-90.
3. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985, 14:375-403.
4. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006, 79:173-189.
5. Bhat R.V., Leonov S., Luthman J., Scott C.W., Lee C.-M. Interactions between GSK3beta and caspase signalling pathways during NGF deprivation induced cell death. J Alzheimers Dis 2002, 4:291-301.
6. Bijur G.N., De Sarno P., Jope R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 2000, 275:7583-7590.
7. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
8. Chakraborty A., Latapy C., Xu J., Snyder S.H., Beaulieu J.-M. Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Mol Psychiatry 2013, [Epub ahead of print]. 10.1038/mp.2013.21.
9. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999, 96:8745-8750.
10. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004, 18:1162-1164.
11. Chin P.C., Majdzadeh N., D'Mello S.R. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005, 137:193-201.
12. Collino M., Thiemermann C., Mastrocola R., Gallicchio M., Benetti E., Miglio G., et al. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock 2008, 30:299-307.
13. Crespo-Biel N., Canudas A.M., Camins A., Pallàs M. Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochem Int 2007, 50:435-442.
14. Cuzzocrea S., Genovese T., Mazzon E., Crisafulli C., Di Paola R., Muià C., et al. Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 2006, 318:79-89.
15. Dunleavy M., Provenzano G., Henshall D.C., Bozzi Y. Kainic acid-induced seizures modulate Akt (SER473) phosphorylation in the hippocampus of dopamine D2 receptor knockout mice. J Mol Neurosci 2013, 49:202-210.
16. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002, 8:126-132.
17. Facci L., Stevens D.A., Skaper S.D. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 2003, 14:1467-1470.
18. Fujikawa D.G., Shinmei S.S., Zhao S., Aviles E.R. Caspase-dependent programmed cell death pathways are not activated in generalized seizure-induced neuronal death. Brain Res 2007, 1135:206-218.
19. Ge X.-H., Zhu G.-J., Geng D.-Q., Zhang Z.-J., Liu C.-F. Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3b-mediated mitochondrial translocation of Bax in PC12 cells. Neurol Sci 2012, 33:1249-1256.
20. Gillardon F., Wickert H., Zimmermann M. Up-regulation of bax and down-regulation of bcl-2 is associated with kainate-induced apoptosis in mouse brain. Neurosci Lett 1995, 192:85-88.
21. Goodenough S., Conrad S., Skutella T., Behl C. Inactivation of glycogen synthase kinase-3beta protects against kainic acid-induced neurotoxicity in vivo. Brain Res 2004, 1026:116-125.
22. Huang Z., Walker M.C., Shah M.M. Loss of dendritic HCN1 subunits enhances cortical excitability and epileptogenesis. J Neurosci 2009, 29:10979-10988.
23. Jeon B.T., Shin H.J., Kim J.B., Kim Y.K., Lee D.H., Kim K.H., et al. Adiponectin protects hippocampal neurons against kainic acid-induced excitotoxicity. Brain Res Rev 2009, 61:81-88.
24. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29:95-102.
25. Kim D.W., Lee J.H., Park S.K., Yang W.-M., Jeon G.S., Lee Y.H., et al. Astrocytic expressions of phosphorylated Akt, GSK3beta and CREB following an excitotoxic lesion in the mouse hippocampus. Neurochem Res 2007, 32:1460-1468.
26. Kim S.D., Yang S.-I., Kim H.-C., Shin C.Y., Ko K.H. Inhibition of GSK-3beta mediates expression of MMP-9 through ERK1/2 activation and translocation of NF-kappaB in rat primary astrocyte. Brain Res 2007, 1186:12-20.
27. Kinoshita Y., Wenzel H.J., Kinoshita C., Schwartzkroin P.A., Morrison R.S. Acute, but reversible, kainic acid-induced DNA damage in hippocampal CA1 pyramidal cells of p53-deficient mice. Epilepsia 2012, 1 (Suppl.):125-133.
28. Kitano Y., Komiyama C., Makino M., Takasuna K., Satoh H., Aoki T., et al. Anticonvulsant and neuroprotective effects of the novel nootropic agent nefiracetam on kainic acid-induced seizures in rats. Brain Res 2005, 1057:168-176.
29. Kondratyev A., Gale K. Intracerebral injection of caspase-3 inhibitor prevents neuronal apoptosis after kainic acid-evoked status epilepticus. Brain Res Mol Brain Res 2000, 75:216-224.
30. Kotliarova S., Pastorino S., Kovell L.C., Kotliarov Y., Song H., Zhang W., et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 2008, 68:6643-6651.
31. Leng Y., Liang M.-H., Ren M., Marinova Z., Leeds P., Chuang D.-M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008, 28:2576-2588.
32. Linseman D.A., Butts B.D., Precht T.A., Phelps R.A., Le S.S., Laessig T.A., et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004, 24:9993-10002.
33. Liu W., Akhand A.A., Takeda K., Kawamoto Y., Itoigawa M., Kato M., et al. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ 2003, 10:772-781.
34. Luan G., Zhao Y., Zhai F., Chen Y., Li T. Ketogenic diet reduces Smac/Diablo and cytochrome c release and attenuates neuronal death in a mouse model of limbic epilepsy. Brain Res Bull 2012, 89:79-85.
35. Luna-Medina R., Cortes-Canteli M., Sanchez-Galiano S., Morales-Garcia J.A., Martinez A., Santos A., et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci 2007, 27:5766-5776.
36. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784.
37. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002, 22:373-384.
38. McKhann G.M., Wenzel H.J., Robbins C.A., Sosunov A.A., Schwartzkroin P.A. Mouse strain differences in kainic acid sensitivity, seizure behavior, mortality, and hippocampal pathology. Neuroscience 2003, 122:551-561.
39. Naegele J.R. Neuroprotective strategies to avert seizure-induced neurodegeneration in epilepsy. Epilepsia 2007, 48(Suppl. 2):107-117.
40. Narkilahti S., Nissinen J., Pitkänen A. Administration of caspase 3 inhibitor during and after status epilepticus in rat: effect on neuronal damage and epileptogenesis. Neuropharmacology 2003, 44:1068-1088.
41. Noh H.S., Kim Y.S., Kim Y.H., Han J.Y., Park C.H., Kang A.K., et al. Ketogenic diet protects the hippocampus from kainic acid toxicity by inhibiting the dissociation of bad from 14-3-3. J Neurosci Res 2006, 84:1829-1836.
42. Park H.J., Kim H.J., Park H.J., Ra J., Zheng L.T., Yim S.V., et al. Protective effect of topiramate on kainic acid-induced cell death in mice hippocampus. Epilepsia 2008, 49:163-167.
43. Paxinos G., Franklin K. Paxinos and Franklin's the mouse brain in stereotaxic coordinates 2012, Academic Press, San Diego. 4th ed.
44. Perucca P., Gilliam F.G. Adverse effects of anti-epileptic drugs. Lancet Neurol 2012, 11:792-802.
45. Pitkänen A. Therapeutic approaches to epileptogenesis-hope on the horizon. Epilepsia 2010, 51(Suppl. 3):2-17.
46. Puig B., Ferrer I. Caspase-3-associated apoptotic cell death in excitotoxic necrosis of the entorhinal cortex following intraperitoneal injection of kainic acid in the rat. Neurosci Lett 2002, 321:182-186.
47. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
48. Rojo A.I., Rada P., Egea J., Rosa A.O., López M.G., Cuadrado A. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol Cell Neurosci 2008, 39:125-132.
49. Rosa A.O., Egea J., Martínez A., García A.G., López M.G. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. Exp Neurol 2008, 212:93-99.
50. Sánchez-Gómez M.V., Alberdi E., Pérez-Navarro E., Alberch J., Matute C. Bax and calpain mediate excitotoxic oligodendrocyte death induced by activation of both AMPA and kainate receptors. J Neurosci 2011, 31:2996-3006.
51. Sloviter R.S., Damiano B.P. On the relationship between kainic acid-induced epileptiform activity and hippocampal neuronal damage. Neuropharmacology 1981, 20:1003-1011.
52. Sperk G. Kainic acid seizures in the rat. Prog Neurobiol 1994, 42:1-32.
53. Tripathi P.P., Santorufo G., Brilli E., Borrelli E., Bozzi Y. Kainic acid-induced seizures activate GSK-3β in the hippocampus of D2R-/- mice. Neuroreport 2010, 21:846-850.
54. Vohora D., Pal S.N., Pillai K.K. Histamine and selective H3-receptor ligands: a possible role in the mechanism and management of epilepsy. Pharmacol Biochem Behav 2001, 68:735-741.
55. Walker M.C., White H.S., Sander J.W. Disease modification in partial epilepsy. Brain 2002, 125:1937-1950.
56. Wang Z., Havasi A., Gall J., Bonegio R., Li Z., Mao H., et al. GSK3beta promotes apoptosis after renal ischemic injury. J Am Soc Nephrol 2010, 21:284-294.
57. Wei X.-W., Yan H., Xu B., Wu Y.-P., Li C., Zhang G.-Y. Neuroprotection of co-activation of GABA receptors by preventing caspase-3 denitrosylation in KA-induced seizures. Brain Res Bull 2012, 88:617-623.
58. WHO Epilepsy Key facts 2012, Available at: http://www.who.int/mediacentre/factsheets/fs999/en. Retrieved 01.09.13.
59. Xiao G., Hu W., Chen X. Magnesium lithospermate B protects neurons from N-methyl-d-aspartic acid injury and attenuates kainic acid-induced neurodegeration in FVB mice. J Mol Neurosci 2013, 10.1007/s12031-013-0023-7.
60. Xie N., Li H., Wei D., LeSage G., Chen L., Wang S., et al. Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis. Neuropharmacology 2010, 59:444-451.
61. Zhang F., Phiel C.J., Spece L., Gurvich N., Klein P.S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium, Evidence for autoregulation of GSK-3. J Biol Chem 2003, 278:33067-33077.
62. Zhang J., Yan H., Wu Y.-P., Li C., Zhang G.-Y. Activation of GluR6-containing kainate receptors induces ubiquitin-dependent Bcl-2 degradation via denitrosylation in the rat hippocampus after kainate treatment. J Biol Chem 2011, 286:7669-7680.